Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared David H Aggen’s, Assistant Attending at Memorial Sloan Kettering Cancer Center, post on X, adding:
“Novel Topo1 ADC for urothelial cancer
- ORR in TOPO1-ADC naive: 42%
- ORR in TOPO1-ADC refractory: 0%
The pattern holds across diseases.”
Quoting David H Aggen’s post:
“LY405231 a topo-I nectin-4 targeted ADC retains clinical activity post EV/P. Presented by Gopa Iyer.
- ORR 42%
- Prior Topo-i exposure 0% (0/18 responses)
- Increwased toxicity in the 7% of patients with low CYP2D6 activity score – one of the first markers of increased toc with a topo-I drug.”
Other articles featuring Paolo Tarantino and David H Aggen on OncoDaily.
